EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series

Aqsa Ashraf, Rebekah Kuhlman, Osman Khan, Sanober Nusrat

Journal of Thrombosis and Haemostasis · 2026-11 · 24 (11) · 3939-3942

DOI: 10.1016/j.jtha.2026.08.022 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-11. Verfasst von Aqsa Ashraf und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology-Oncology Section, Department of Internal Medicine, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, Oklahoma, USA…. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Immune Tolerance, Blood Coagulation Factor Inhibitors. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The University of Oklahoma Health Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of neutralizing factor VIII (FVIII) inhibitors remains a major therapeutic challenge in severe hemophilia A. We report 2 patients with complex inhibitor histories who achieved rapid, sustained inhibitor eradication with efanesoctocog alfa. Immune tolerance induction was initiated at 100 U/kg 3 times weekly, with subsequent dose reduction after inhibitor clearance. Inhibitor titers declined to undetectable levels (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIImmune ToleranceBlood Coagulation Factor InhibitorsCoagulantsRecombinant Fusion ProteinsHumansMaleTreatment OutcomeAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingSeverity of Illness IndexAntibodies, BispecificDrug Administration ScheduleTime FactorsAdult

Stichwörter der Autor:innen

factor VIIIhemophilia Aimmune tolerance inductionneutralizing antibodyrecombinant fusion protein

Substanzen

Factor VIIIF8 protein, humanAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingemicizumabBlood Coagulation Factor InhibitorsCoagulantsRecombinant Fusion ProteinsAntibodies, Bispecific

Autor:innen und Institutionen

  • Hematology-Oncology Section, Department of Internal Medicine, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, Oklahoma, USA. Electronic address: aqsa-ashraf@ou.edu.
  • Department of Internal Medicine, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, Oklahoma, USA.
  • Department of Pediatrics, Oklahoma Center for Bleeding and Clotting Disorders, University of Oklahoma Health Campus, Oklahoma City, Oklahoma, USA.
  • Hematology-Oncology Section, Department of Internal Medicine, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, Oklahoma, USA.

Förderung

  • The University of Oklahoma Health Sciences

Zitieren

APA

Ashraf, A., Kuhlman, R., Khan, O., & Nusrat, S. (2026). Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series. Journal of Thrombosis and Haemostasis, 24(11), 3939-3942. https://doi.org/10.1016/j.jtha.2026.08.022

Vancouver

Ashraf A, Kuhlman R, Khan O, Nusrat S. Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series. Journal of Thrombosis and Haemostasis. 2026;24(11):3939-3942. doi:10.1016/j.jtha.2026.08.022

BibTeX
@article{Ashraf2026,
  author = {Ashraf, Aqsa and Kuhlman, Rebekah and Khan, Osman and Nusrat, Sanober},
  title = {Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {11},
  pages = {3939--3942},
  doi = {10.1016/j.jtha.2026.08.022}
}
Kostenlos starten →